Maximising SHO training by inclusion of research fellows into a novel hybrid rota.

Por Wilson, Timothy R., Wilson, Jeremy I., Alexander, David J.
Publicado em 2005

Whose Appendicectomy? – Do Laparoscopic Appendicectomies Impair SHO Training?

Por Owais, Anwar E, Wilson, Timothy R, Sethi, Neeraj, Aldoori, Munther I
Publicado em 2008

Inflammatory fibroid polyp (Vanek's tumour), an unusual large polyp of the jejunum: a case report

Por Rehman, Shafiq, Gamie, Zakareya, Wilson, Timothy R, Coup, Andrew, Kaur, Geetinder
Publicado em 2009

Could pre-mortem computerised tomography scans reduce the need for coroner's post-mortem examinations?

Por Owais, Anwar E, Wilson, Timothy R, Khan, Shakeeb A, Jaidev, Jo, Renwick, Ian, Mitchell, Charles, Macfie, John
Publicado em 2010

UK-based, multisite, prospective cohort study of small bowel obstruction in acute surgical services: National Audit of Small Bowel Obstruction (NASBO) protocol

Por Lee, Matthew J, Sayers, Adele E, Drake, Thomas M, Hollyman, Marianne, Bradburn, Mike, Hind, Daniel, Wilson, Timothy R, Fearnhead, Nicola S
Publicado no BMJ Open (2017)

The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase

Por Hoeflich, Klaus P., Guan, Jane, Edgar, Kyle A., O'Brien, Carol, Savage, Heidi, Wilson, Timothy R., Neve, Richard M., Friedman, Lori S., Wallin, Jeffrey J.
Publicado no Genes Cancer (2016)

EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling

Por Wilson, Kristy J., Mill, Christopher, Lambert, Sydney, Buchman, Jennifer, Wilson, Timothy R., Hernandez-Gordillo, Victor, Gallo, Richard M., Ades, Laura M.C., Settleman, Jeffrey, Riese, David J.
Publicado em 2012

Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition

Por Edgar, Kyle A., Crocker, Lisa, Cheng, Eric, Wagle, Marie-Claire, Wongchenko, Matthew, Yan, Yibing, Wilson, Timothy R., Dompe, Nicholas, Neve, Richard M., Belvin, Marcia, Sampath, Deepak, Friedman, Lori S., Wallin, Jeffrey J.
Publicado em 2014

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Por Wilson, Timothy R., Fridlyand, Jane, Yan, Yibing, Penuel, Elicia, Burton, Luciana, Chan, Emily, Peng, Jing, Lin, Eva, Wang, Yulei, Sosman, Jeff, Ribas, Antoni, Li, Jiang, Moffat, John, Sutherlin, Daniel P., Koeppen, Hartmut, Merchant, Mark, Neve, Richard, Settleman, Jeff
Publicado em 2012

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Por Spoerke, Jill M., Gendreau, Steven, Walter, Kimberly, Qiu, Jiaheng, Wilson, Timothy R., Savage, Heidi, Aimi, Junko, Derynck, Mika K., Chen, Meng, Chan, Iris T., Amler, Lukas C., Hampton, Garret M., Johnston, Stephen, Krop, Ian, Schmid, Peter, Lackner, Mark R.
Publicado no Nat Commun (2016)

Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers

Por Schleifman, Erica B., Desai, Rupal, Spoerke, Jill M., Xiao, Yuanyuan, Wong, Cheryl, Abbas, Ilma, O’Brien, Carol, Patel, Rajesh, Sumiyoshi, Teiko, Fu, Ling, Tam, Rachel N., Koeppen, Hartmut, Wilson, Timothy R., Raja, Rajiv, Hampton, Garret M., Lackner, Mark R.
Publicado em 2014

Phase I Dose Escalation Study of Taselisib (GDC-0032), an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Por Juric, Dejan, Krop, Ian, Ramanathan, Ramesh K., Wilson, Timothy R., Ware, Joseph A., Sanabria Bohorquez, Sandra M., Savage, Heidi M., Sampath, Deepak, Salphati, Laurent, Lin, Ray S., Jin, Huan, Parmar, Hema, Hsu, Jerry Y., Von Hoff, Daniel D., Baselga, Jose
Publicado no Cancer Discov (2017)

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples

Por Wilson, Timothy R., Xiao, Yuanyuan, Spoerke, Jill M., Fridlyand, Jane, Koeppen, Hartmut, Fuentes, Eloisa, Huw, Ling Y., Abbas, Ilma, Gower, Arjan, Schleifman, Erica B., Desai, Rupal, Fu, Ling, Sumiyoshi, Teiko, O’Shaughnessy, Joyce A., Hampton, Garret M., Lackner, Mark R.
Publicado no Breast Cancer Res Treat (2014)

High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck

Por Shames, David S., Carbon, Juliet, Walter, Kim, Jubb, Adrian M., Kozlowski, Cleopatra, Januario, Tom, An, Do, Fu, Ling, Xiao, Yuanyuan, Raja, Rajiv, Jiang, Brittany, Malekafzali, Ashi, Stern, Howard, Settleman, Jeff, Wilson, Timothy R., Hampton, Garret M., Yauch, Robert L., Pirzkall, Andrea, Amler, Lukas C.
Publicado em 2013

Correction: High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck

Por Shames, David S., Carbon, Juliet, Walter, Kim, Jubb, Adrian M., Kozlowski, Cleopatra, Januario, Tom, Do, An, Fu, Ling, Xiao, Yuanyuan, Raja, Rajiv, Jiang, Brittany, Malekafzali, Ashi, Stern, Howard, Settleman, Jeff, Wilson, Timothy R., Hampton, Garret M., Yauch, Robert L., Pirzkall, Andrea, Amler, Lukas C.
Publicado em 2013

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population

Por Wilson, Timothy R, Yu, Jianjun, Lu, Xuyang, Spoerke, Jill M, Xiao, Yuanyuan, O’Brien, Carol, Savage, Heidi M, Huw, Ling-Yuh, Zou, Wei, Koeppen, Hartmut, Forrest, William F, Fridlyand, Jane, Fu, Ling, Tam, Rachel, Schleifman, Erica B, Sumiyoshi, Teiko, Molinero, Luciana, Hampton, Garret M, O’Shaughnessy, Joyce A, Lackner, Mark R
Publicado no NPJ Breast Cancer (2016)